Yandi

Quick links to important sections

Yandi

Method of action: Antiemetic

Treatment option: Burping

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yandi

Quick Facts

Property Description
Active ingredient Tropisetron (INN)
Form Solution for Injection/Infusion, Tablet/Capsule
Pharmacological class Selective Serotonin 5-HT3 Receptor Antagonist
General purpose Prevention and control of nausea and vomiting (emesis)
Origin Synthetic (Indole derivative)

Yandi: Defining the Antiemetic Agent

Yandi is a highly effective, prescription-only (POM/S4) medicine defined as an antiemetic agent used to prevent and control the sensations of nausea and the reflex of emesis. The active component, Tropisetron, is pharmacologically classified as a Selective Serotonin 5-HT3 Receptor Antagonist. This pharmacological class is clinically recognized for its high specificity in managing severe nausea and vomiting. The drug's central function is to provide relief by specifically interrupting the body's internal signals that trigger the vomiting response.

Composition, Origin, and Available Forms

The core of Yandi is its active ingredient, Tropisetron (often supplied as the hydrochloride salt), which is a synthetic compound structurally based on the indole system. Tropisetron has an established action that helps suppress acute episodes of vomiting and nausea. Yandi is a single active substance product available in distinct dosage forms to suit different needs. These forms include an aqueous solution for injection/infusion—which allows for administration when oral intake is compromised—and solid preparations like a tablet or capsule intended for oral administration.

How Yandi Controls the Vomiting Reflex

Yandi controls the reflex by performing a direct 5-HT3 receptor blockade, a mechanism that acts like a specific chemical barrier. The active substance, Tropisetron, competitively blocks the receptors that respond to the chemical messenger serotonin (5-HT). By inhibiting the activity of serotonin at key sites, such as the nerve terminals in the gut and the Chemoreceptor Trigger Zone (CTZ) in the brain, Yandi prevents the transmission of the signal that tells the body to initiate nausea and the subsequent act of vomiting. This specific mechanism underlies the general benefit of reliably suppressing the emetic reflex.

Regulatory References

  1. WHO Essential Medicines List: Tropisetron
  2. EMA Product Information

What side effects are possible with Yandi?

The official safety profile for Yandi (Tropisetron) is organized by regulatory authorities into categories that describe the type and frequency of documented adverse reactions, which are generally transient at the recommended dose.

Documented Adverse Reactions

The most frequently reported side effects are classified as common in official labeling, primarily affecting the nervous and gastrointestinal systems.

Classification System-Organ Class (SOC) Example Reactions (Label-Documented)
Common Nervous System, Gastrointestinal Headache, Constipation
Less Frequent Nervous System, Gastrointestinal Dizziness/Light-headedness, Tiredness/Fatigue, Abdominal pain, Diarrhoea

Serious reactions are also documented, although they are rare. Serious adverse reactions officially listed include signs of hypersensitivity/anaphylaxis (such as rash, wheezing, and swelling) and, in very rare instances, reports of collapse and cardiovascular arrest.

Population-Specific Safety Notes

Regulatory documentation includes specific safety constraints for certain patient groups:

  • Cardiac Patients: Caution is advised for individuals with pre-existing cardiac rhythm or conduction disturbances.
  • Hepatic/Renal Impairment: Special precautions are noted for patients with pre-existing kidney or liver problems.
  • Poor Metabolizers: Individuals known to be poor metabolizers of the CYP2D6 enzyme may experience common side effects, such as headache and constipation, that are slightly more intense or last longer.
  • Pregnancy and Lactation: Tropisetron is contraindicated during pregnancy and lactation due to insufficient data or unknown excretion into human milk.

Functional safety notes in the official label include a restriction on activities like driving or operating machinery due to the potential for the medicine to cause dizziness or tiredness.

Overdose and Emergency Response

The official documentation regarding Yandi (Tropisetron) overdose details specific manifestations and mandates immediate emergency action when severe symptoms are present. Overexposure may present with common clinical signs, including headache, dizziness, fatigue, and somnolence. Gastrointestinal disturbances such as abdominal pain, constipation, or diarrhea may also be observed. Regulatory information notes that severe presentations may involve signs of hypersensitivity, such as hypotension or acute bronchospasm.

Severe or life-threatening outcomes documented in the official profile include cardiovascular collapse and cardiovascular arrest. Due to the pharmacological class, the potential for QTc prolongation requires specialized supportive management. When any severe or life-threatening manifestation is suspected, immediate medical attention must be sought as explicitly stated in regulatory instructions.

There is no specific antidote known for Tropisetron overdose. Management is officially described as symptomatic and supportive treatment to maintain all vital functions. Because of the inherent risk of cardiac effects, close hospital monitoring, including continuous electrocardiogram (ECG) monitoring, is a necessary procedural step. Official prescribing information identifies population-specific considerations, noting that poor metabolizers of CYP2D6 may have increased plasma concentrations, potentially increasing the risk of dose-related toxicity. Patients with uncontrolled hypertension may also face an increased risk of elevated blood pressure if administered high daily doses.

Therapeutic Uses of Yandi

Yandi (Tropisetron) is generally used in situations involving certain distressing symptoms. The compound is widely recognized for its role in the symptomatic management of nausea and vomiting associated with cancer treatment and following surgery.

This medication is generally applicable within clinical settings that involve acute or disruptive symptom patterns, relevant for conditions where symptoms may intensify temporarily, such as those associated with chemotherapy, radiation, or the perioperative phase. It is applied in addressing symptom clusters that may become intense or disruptive, including the physical act of vomiting and the distressing sensation of nausea. This symptomatic relief generally contributes to easing the overall symptom load during periods of heightened symptoms.


Therapeutic Contexts

The contexts where this support is relevant generally include:

  • Chemotherapy-Induced Nausea and Vomiting (CINV): Used in situations involving recurrent or episodic manifestations.
  • Postoperative Nausea and Vomiting (PONV): Applied when symptoms create noticeable functional strain in the recovery phase.

Quick Fact: Symptomatic Focus

“This symptomatic support is generally relevant when supportive symptom management is appropriate, applied in addressing pronounced manifestations like acute emesis and associated discomfort.”

Regulatory References

  1. NCI Dictionary of Cancer Terms

Eligibility and Restrictions for Use

Yandi is a combination oral contraceptive pill generally used for the prevention of pregnancy in women who have reached menarche. It contains two active ingredients: a progestin (drospirenone) and an estrogen (ethinyl estradiol).


Who Can Use Yandi?

Generally, Yandi is suitable for women who require contraception and do not have medical conditions that would increase the risk of serious side effects. Use should only begin after a thorough medical evaluation by a healthcare provider.

Suitable For
Women seeking a highly effective contraceptive method.
Women who can commit to taking a pill daily.
Women whose medical history does not include contraindications (see below).

Who Should Not Use Yandi?

Yandi is contraindicated in several conditions due to the risk of serious adverse events, particularly blood clots. Patients must inform their doctor about all medical history and current medications before starting Yandi.

Do Not Use Yandi If You Have or Have a History of:
Blood clots (deep vein thrombosis, pulmonary embolism) or a predisposition to them.
Cardiovascular disease, including stroke, heart attack, or certain heart valve problems.
Severe or uncontrolled hypertension or diabetes with vascular damage.
Migraine headaches with aura or are over 35 and have any migraines.
Known or suspected breast cancer or other estrogen-dependent tumors.
Liver disease (including liver tumors) or unexplained abnormal vaginal bleeding.
Severe renal impairment or adrenal insufficiency, due to the drospirenone component.
Smoking heavily (more than 15 cigarettes daily) and are over the age of 35.

Note: Yandi is not for use during pregnancy, and its use is not indicated for women who are post-menopausal or under the age of 18.

What should I know about interactions with other medicines?

Yandi Interactions with other medicines and products

Official regulatory documents define the interaction profile of Yandi (Tropisetron) primarily through its metabolic pathway and potential for additive pharmacodynamic effects.

Interaction Type Interacting Substances/Conditions
Pharmacokinetic (Exposure Change) Liver enzyme inducers (e.g., Rifampicin, Phenobarbital)
Pharmacodynamic (Additive Effect) Drugs that prolong the QT interval (e.g., some anti-arrhythmics)
Substance Restriction Alcohol consumption
Population-Specific Note Poor metabolizers (CYP2D6 polymorphism)

Co-administration with enzyme-inducing medicines, such as Rifampicin or Phenobarbital, constitutes a pharmacokinetic interaction that officially results in lower plasma concentrations of Tropisetron. In extensive metabolizers, this effect may require an adjustment to the Yandi dosage.

A significant pharmacodynamic interaction risk is noted with other medicines that prolong the QT interval, including certain anti-arrhythmics or beta-adrenergic blocking agents. This combination increases the risk of additive QTc interval prolongation, a clinically significant consideration.

For individuals identified as poor metabolizers of Tropisetron, regulatory information indicates a prolonged elimination half-life of the medicine. Furthermore, an interaction-related restriction is stipulated: daily doses above 10 mg must be avoided in patients with uncontrolled hypertension. Finally, the official guidance for this product includes a specific restriction to avoid alcohol consumption.

Mechanism of Action

The mechanism of Yandi, driven by the active substance Tropisetron, is a selective mechanistic action that leads to the functional inhibition of the neural pathways of the emetic reflex.

5-HT3 Receptor: The Core Molecular Target

Tropisetron acts as a selective antagonist that physically blocks the Serotonin 5-HT3 receptor, a crucial ligand-gated ion channel. This competitive molecular interaction prevents the endogenous chemical messenger, Serotonin (5-HT), from binding and initiating a neural impulse. By inhibiting the electrical activity at this first step, the drug effectively modifies the molecular and cellular steps that lead to systemic physiological outcomes.

Dual Interruption of the Emetic Reflex Pathway

The physiological effect relies on the drug's simultaneous central and peripheral action. Peripherally, it blocks receptors on vagal afferent nerve terminals in the gut, intercepting signals before they travel to the brain. Centrally, it deactivates the Chemoreceptor Trigger Zone (CTZ), which monitors the bloodstream for emetic stimuli. This dual interruption ensures the total elimination of the 5-HT3-mediated neural input to the Vomiting Center, which leads to the profound functional inhibition of activity within the reflex pathways.

Mechanistic Specificity and Constraints

The mechanism is restricted to modulating pathways where Serotonin is the dominant emetic trigger. The strong selectivity of the antagonism means that while it exhibits maximal functional relevance in contexts where 5-HT signaling is excessive, its functional effect is physiologically constrained in scenarios where the emetic response is primarily driven by alternative neurotransmitter systems, such as the Dopamine D2 or Neurokinin-1 (NK1) pathways.

Dosage and Administration Information

How to Use Yandi (Enzalutamide) — Administration Guidelines

This section outlines the standardized usage instructions for Yandi (Enzalutamide). It does not cover therapeutic indications, safety, or side effects.


Administration Protocol

Administration Scope Official Instruction
Route of Administration Oral
Standard Dosing Schedule 160 mg administered once daily (QD).
Timing in Relation to Meals May be taken with or without food.
Tablet/Capsule Handling Swallow the tablet or capsule whole. Do not chew, crush, dissolve, or open it.

Procedural Rules and Dose Management

Co-Therapy and Duration:

Treatment often requires concurrent administration with a gonadotropin-releasing hormone (GnRH) analog or previous bilateral orchiectomy. The medicine is intended to be administered until disease progression or unacceptable toxicity.

Missed Dose Instructions:

If a dose is missed, the prescribed dose should be taken as soon as it is remembered on the same day. If the dose is not taken until the next day, the missed dose must be skipped and the regular schedule resumed; do not take two doses to make up for the missed one.

Dose Adjustments:

Protocols include specific dose reductions for concurrent use with strong CYP2C8 inhibitors (dose reduced to 80 mg once daily) and dose increases for concurrent use with strong CYP3A4 inducers (dose increased to 240 mg once daily). Furthermore, the dose must be temporarily withheld or reduced (to 120 mg or 80 mg) if a severe, intolerable adverse reaction occurs.

Recent Clinical Evidence

Research evidence / Overview of studies for Yandi

Evidence for use in Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Research related to Yandi in non-metastatic castration-resistant prostate cancer (nmCRPC) was primarily explored in large, randomized, placebo-controlled clinical trials. These studies were conducted in patient populations where the condition has stopped responding to initial hormone therapy but has not yet been detected spreading. Researchers monitored metastasis-free survival (MFS) and time to chemotherapy initiation. The findings describe patterns observed in the studies where measurements of MFS were reported for the group receiving the study compound and compared to the placebo group. The results apply only to the populations studied, and long-term effects are not fully established for all possible outcomes.


Evidence for use in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

For metastatic castration-sensitive prostate cancer (mCSPC), the evidence was evaluated in major Phase 3 randomized clinical trials. These studies compared Yandi plus standard hormone therapy (ADT) against comparator groups. The research examined overall survival (OS) and radiographic progression-free survival (rPFS). Studies explored these outcomes, and the findings indicate patterns related to measurements of median survival and time to radiographic progression in the study compound groups compared to the comparator groups. Comparative evidence is lacking from direct, head-to-head trials against all contemporary treatment options.


Research in Special Populations

Research has explored the outcomes related to systemic or functional imbalance in special groups, including older adults in the main trials. However, data for certain groups remain insufficient. For instance, limited information is available for patients with conditions associated with acute or disruptive episodes, as these patients were often excluded from or underrepresented in the pivotal trials. Few data are available for patients who are not otherwise healthy enough to meet the rigorous inclusion criteria of large Phase 3 trials.

Key Studies & References FDA approves enzalutamide for metastatic castration-resistant prostate cancer post docetaxel (AFFIRM Trial Summary)

Frequently Asked Questions (FAQ)

Common questions about Yandi (FAQ)

Q: Is Yandi considered a first-line treatment option for its approved use?

In medical guidelines, Yandi (Tropisetron) is often described as a treatment option used for preventing acute nausea and vomiting. This is typically when the drug is used in combination with a corticosteroid to manage symptoms caused by moderately to severely emetogenic chemotherapy.

Q: How quickly can I expect to notice the effects of Yandi?

Following oral administration, official pharmacokinetic data shows that Yandi is rapidly absorbed into the body. Peak concentration in the blood is usually reached within about three hours. The drug's effect is described as sustained, lasting approximately 24 hours.

Q: Does Yandi start working right away, or does it take time to build up in the system?

Yandi is designed to be rapidly absorbed, meaning its active substance is available in the body relatively quickly. It is an antiemetic that is intended to provide a sustained effect over a 24-hour period, and it does not typically require a build-up phase to start working.

Q: How long does Yandi stay in your system after stopping use?

For most people (extensive metabolizers), the medicine's elimination half-life is around 8 hours. However, official labeling notes that in a small percentage of individuals classified as 'poor metabolizers,' this half-life can be extended significantly, potentially lasting up to approximately 45 hours.

Q: Does Yandi cause weight gain or weight loss?

Official drug labels, which document reported adverse reactions, do not list weight gain or weight loss as a documented side effect of Yandi.

Q: Does Yandi interact with common over-the-counter pain relievers like ibuprofen?

Official regulatory documents do not list common over-the-counter pain relievers like ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) as interacting substances. It is generally advised that patients inform their healthcare provider about all over-the-counter medicines and supplements they use.

Q: Does Yandi interact with vitamins or common herbal supplements?

Regulatory labels do not list specific vitamins or common herbal supplements as interacting substances that affect Yandi. The guidance on drug interactions focuses mainly on prescription medicines that affect certain liver enzymes. However, official guidance advises that patients inform their healthcare provider of all supplements they use.

Q: Does Yandi carry any information about potential effects on fertility?

The official product information and nonclinical toxicology data for Yandi do not contain specific information describing effects on human fertility.

Q: What is the difference between the brand name Yandi and its generic ingredient?

The generic medicine (Tropisetron) contains the exact same active ingredient as the brand name (Yandi). All generic medicines are required by the regulatory authorities to meet the same strict standards for quality, strength, and efficacy as the original brand-name product.

Q: Does Yandi work differently for men and women?

Official clinical data does not indicate that the drug's mechanism of action or efficacy is different based on patient gender.

Q: Is Yandi a controlled substance?

According to the official schedules maintained by the Drug Enforcement Administration (DEA) and similar international bodies, Yandi (Tropisetron) is not classified as a controlled substance.

Q: Do I need to have regular blood tests while using Yandi?

Routine monitoring with regular blood tests is not typically required for patients using Yandi for its approved short-term antiemetic use. Any necessary monitoring should be discussed with the patient's healthcare provider.

Q: What is the risk of stopping Yandi suddenly?

The official product information does not document a physical withdrawal syndrome or specific adverse events associated with abrupt discontinuation.

Q: Does Yandi require special monitoring for low blood sugar or other vitals?

The official documentation does not mandate special monitoring for conditions like low blood sugar (hypoglycemia) or other specific vital signs beyond standard clinical practice.

Q: Can Yandi cause sun sensitivity or skin reactions?

The regulatory label documents adverse events such as rash and other signs of hypersensitivity. However, there is no specific mention of sun sensitivity (photosensitivity) in the official adverse reaction list.

Q: Does Yandi have a known effect on sleep patterns or overall energy levels?

Tiredness, fatigue, or sleepiness are listed as less frequent side effects in the official regulatory documentation.

Q: Can Yandi affect liver function test results?

Official labeling notes that transient and typically temporary increases in certain liver enzymes (like AST and ALT) may occur, particularly in patients receiving highly emetogenic chemotherapy. These changes are generally asymptomatic.

Q: Are there any known side effects that affect mood, anxiety, or mental clarity?

Official documentation lists central nervous system (CNS) effects, such as dizziness or light-headedness, as less frequent side effects. Other side effects specifically related to changes in mood or anxiety are not commonly documented.

Q: What does the term 'contraindication' mean in the context of Yandi?

A contraindication refers to a specific condition or circumstance where the medicine is generally not recommended for use, as it may pose a health risk. The official documentation lists the conditions where Yandi should not be used.

Q: Is it necessary to avoid any specific foods or drinks while using Yandi?

Official guidance includes a specific limitation regarding alcohol consumption while using this product. However, the medicine may otherwise be taken with or without food.

How should Yandi be stored and disposed of?

How to Store and Dispose of Yandi

The storage and disposal of Yandi (Tropisetron) must strictly follow the requirements documented in official regulatory labeling.

Storage Requirements

The unopened injection vials must be stored at a temperature not exceeding 30 C and must not be frozen. The product should remain in its original package to protect it from light and moisture. Once the injection solution is diluted for infusion, it has a strict in-use stability period and must be used within eight hours of preparation, even if refrigerated, due to microbial risk.

Storage Constraint Requirement
Temperature Below 30 C (Do not freeze)
In-Use Time Use within 8 hours of dilution
Child Safety Keep out of the sight and reach of children

Disposal Instructions

Unused or expired medicine should be returned using a drug take-back program or a DEA-authorized collector as the preferred disposal method. If no take-back option is available, the medicine must be mixed with an undesirable substance (e.g., dirt) before being sealed and discarded in the household trash. Empty packaging must have all personal information concealed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yandi found in:

A-Z Index: